MERTK antibody (Extracellular, N-Term)

Catalog No. ABIN7884799

The Rabbit Polyclonal anti-MERTK antibody is suitable to detect MERTK in samples from Human, Mouse and Rat. It has been validated for WB, IHC, FACS and IF.

Quick Overview for MERTK antibody (Extracellular, N-Term) (ABIN7884799)

Target: MERTK (C-Mer Proto-Oncogene Tyrosine Kinase (MERTK))

Reactivity: Human, Mouse, Rat

Host: Rabbit

Clonality: Polyclonal

Conjugate: This MERTK antibody is un-conjugated

Application: Western Blotting (WB), Immunohistochemistry (IHC), Flow Cytometry (FACS), Immunofluorescence (IF)

Grade: Carrier-free

Product Details anti-MERTK Antibody

Binding Specificity: AA 402-416, Extracellular, N-Term

Purpose: A Rabbit Polyclonal Antibody to MERTK Receptor

Predicted Reactivity: Rat - identical, human - 13,15 amino acid residues identical

Purification: Affinity purified on immobilized antigen.

Immunogen: (C)KPPIKRQDGELVGYR, corresponding to amino acid residues 402 - 416 of mouse MERTK 

Isotype: IgG

Application Details

Application Notes:

WB: 1:400

FC: The optimal concentration should be determined by the user

ICC: The optimal concentration should be determined by the user

IHC: 1:300

IP: The optimal concentration should be determined by the user

Comment:

Negative Control: (ABIN7234888)

Restrictions: For Research Use only

Handling

Format: Lyophilized

Reconstitution: 0.2 mL double distilled water (DDW)

Concentration: 1 mg/mL

Buffer: PBS pH 7.4

Preservative: Without preservative

Storage: -20 °C

Storage Comment: The antibody ships as a lyophilized powder at room temperature. Upon arrival, it should be stored at -20°C

Target Details for MERTK

Target: MERTK (C-Mer Proto-Oncogene Tyrosine Kinase (MERTK))

Alternative Name: Receptor tyrosine kinase MerTK

Background:

Synonyms: Receptor tyrosine kinase MerTK, C-Mer Proto-Oncogene Tyrosine Kinase, Mer, Proto-Oncogene C-Mer

Description: Myeloid-epithelial-reproductive tyrosine kinase, MERTK, is a receptor tyrosine kinase of the TAM (Tyro3, Axl and MERTK) family, expressed in numerous cancers1.The extracellular N-terminal domain contains two immunoglobulin-like and two fibronectin 3 domains, followed by a hydrophobic single pass transmembrane domain, and a cytoplasmic C-terminal tail containing a tyrosine kinase domain1,2.Auto-phosphorylation induced by ligand binding influences a range of downstream signaling pathways and cellular functions2. The physiological roles of MERTK include regulation of tissue homeostasis and repair, innate immune control, and platelet aggregation. However, aberrant expression of this protein promotes neoplasia, cell cycle progression, proliferation and tumor growth, resistance to apoptosis, and promotion of tumor metastases.MERTK is involved in the activation of several canonic oncogenic signaling pathways in various types of cancers including: leukemia, non-small cell lung cancer, glioblastoma, melanoma, prostate cancer, breast cancer, colon cancer and gastric cancer1,3,4.Due to its pivotal role in cancer development and metastasis, multiple therapeutic approaches are currently in development to inhibit MERTK, including ligand "traps" and small-molecule tyrosine kinase inhibitors4.

Gene ID: 17289

UniProt: Q60805

Pathways: RTK Signaling